(TSX-V:PTK),(NASDAQ:POET), TORONTO, July 08, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer(TM), Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today announced the appointment of Sohail Khan as director and […]
NEW YORK, NY / ACCESS Newswire / July 8, 2025 / If you suffered a loss on your DoubleVerify Holdings, Inc. (NYSE:DV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/doubleverify-holdings-inc-lawsuit-submission-form-2?prid=155912&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / July 8, 2025 / If you suffered a loss on your Red Cat Holdings, Inc. (NASDAQ:RCAT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/red-cat-holdings-inc-lawsuit-submission-form?prid=155913&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com
(NASDAQ:JFBR),(NASDAQ:JFBRW), Jeffs' Brands' equity stake in the merged company is 75.02% and may increase to up to 83.29% contingent upon meeting certain pre-determined milestones Tel Aviv, Israel, July 08, 2025 (GLOBE NEWSWIRE) — Jeffs' Brands Ltd (“Jeffs' Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced
(NASDAQ:CBIO), Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced
(TSX-V:STUD),(Boerse Frankfurt – Freiverkehr:HM40.F),(OTC US:STLNF),(Other OTC:STLNF),(Frankfurt:FE0), VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion“) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce that, it has entered into a technology data acquisition agreement (the “Agreement“) dated April 24th, 2025, amongst the Company and Matthew J. Mason
(NASDAQ:PSTV), HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the treatment of its initial patients in the Company's ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment
(NYSE:MLM), RALEIGH, N.C., July 08, 2025 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”), a leading national supplier of aggregates and heavy building materials, today announced the appointment of Michael J. Petro as Senior Vice President and Chief Financial Officer, effective immediately. Robert J. Cardin, who has been serving
(TSX:DNG),(Pinksheets:DNGDF),(PinkSheets:DNGDF), ACQUISITION TO MATERIALLY INCREASE NAMEPLATE PROCESSING CAPACITY POTENTIAL TO UNLOCK ADDITIONAL VALUE THROUGH OPTIMISATION AND EXPANSION OF PURCHASING NETWORK MONTREAL, July 08, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”), is pleased to announce it has signed a share purchase agreement to acquire Arkham Metals SAS (Ecuador) from Pelorus
(TSX:BCT),(NASDAQ:BCTX),(NASDAQ:BCTXW),(NASDAQ:BCTXZ), 52% of BriaCell's most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 months Survival benefit observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors